Cardiac AI Market: Decoding the Billion Dollar Hype

The story pitched to investors about the cardiac AI market is a good one, full of impressive growth projections pointing to the next big thing in healthcare. But for those of us actually working in this field, a look at the real revenue figures shows a huge gap between the headline promises and the money companies are actually banking. You have to understand that chasm to make any sense of it.

Unpacking the Headline Numbers: Promise Versus Penetration

You see these big numbers thrown around, like Mordor Intelligence’s $2.71 billion estimate for the cardiac AI market, which includes everything from imaging and monitoring to risk prediction models. They’ll point to a 26.5% compound annual growth rate through 2030 and the roughly 47 active companies in the space to paint a picture of a booming, competitive field. That’s what gets investors excited, thinking they’ve found a gold rush. But that $2.71 billion figure isn’t real money in the bank for most of these companies. It’s a measure of collective ambition, a total of all the potential applications from AI-powered coronary CT angiography analysis to sophisticated ECG interpretation algorithms, which obscures the fact that revenue is not at all evenly distributed among the players in what looks like one big category. It’s not.

The Concentrated Revenue Reality

The revenue isn’t just concentrated, it’s extremely concentrated. Take HeartFlow, a true AI pioneer for non-invasive coronary physiology assessment. They went public in August 2025, raised $364 million, and posted $212.07 million in revenue for the trailing twelve months ending June 30, 2026, that’s a 42.77% year-over-year growth. That’s a huge achievement, especially after they fought through the FDA 510(k) process and got a CMS National Coverage Determination (NCD) for their coronary CT AI. HeartFlow SEC filings But then you look at a company like iRhythm Technologies in the cardiac monitoring segment, and they’re projecting $880 million to $890 million for the full year 2026. iRhythm isn’t a pure AI-native startup. They use advanced algorithms for arrhythmia detection inside a more established business model, which shows just how much money is in monitoring when you add good analytics. The massive gap between iRhythm’s revenue and HeartFlow’s, even though both are technically “cardiac AI,” tells you everything about the different maturity levels of these sub-segments. This is the detail investors need to see. That $2.71 billion market estimate is measuring the promise of the whole field, not the realized scale for the majority of the 47 active companies. Most of those are probably still in early-stage development or clinical trials with little to no revenue. And good luck to them (they’ll need it), because established players like iRhythm have built a huge “data moat” from their extensive proprietary datasets, making it almost impossible for a new company to compete on accuracy without spending a fortune on data acquisition and model refinement.

Regulatory Gates: The Determinants of Revenue Conversion

So how does a company turn a cool piece of cardiac AI into actual, sustainable revenue? It all comes down to two gates: getting FDA 510(k) clearance (or a De Novo classification for something truly new) and then securing a CMS National Coverage Determination (NCD) or at least a local coverage determination (LCD). These aren’t just paperwork. They’re the absolute deciders of who makes money and who doesn’t.

FDA Clearance: The Entry Point for Market Access

Any AI that counts as Software as a Medical Device (SaMD) has to get past the FDA. No exceptions. The most common path is the 510(k), where you have to prove your device is substantially equivalent to something already on the market, which requires solid clinical evidence from retrospective or even prospective studies showing it’s safe and effective. If a company can get this done quickly, maybe by finding a great predicate device to compare against or having a smart Predetermined Change Control Plan (PCCP) for their adaptive AI/ML models, they get a massive head start. Without that FDA clearance, you can’t legally sell your product for diagnosis or treatment in the United States. Your revenue is zero. It’s that simple. FDA 510(k) database

CMS Coverage: The Gateway to Reimbursement and Adoption

Getting FDA clearance is only step one. You’re still not going to make any money until you figure out reimbursement. The absolute jackpot is a CMS National Coverage Determination, which gives you broad Medicare coverage and basically tells private insurance companies that your tech is worth paying for. Getting an NCD, like HeartFlow did, is a beast of a process. You need a mountain of evidence showing clinical utility, better patient outcomes, and that it’s cost-effective. If you don’t have a clear CPT code and a payment pathway, your fancy AI gets stuck in a research-only or self-pay ghetto, killing its total addressable market (TAM). This whole process takes a long time because companies have to prove their value proposition to healthcare systems, often generating real-world evidence (RWE) to show their tech works outside of pristine trial conditions. For an investor, is there a clear reimbursement strategy? That question is just as important as how the tech works. A cardiac AI tool without a path to getting paid is dead on arrival from a business standpoint.

Conclusion: Beyond the Hype, Towards Real Value

There’s no question the cardiac AI market will get bigger. The tech is getting better and we absolutely need faster, more accurate ways to handle cardiovascular care. But investors and analysts need to look past the hype. Those big market estimates are about potential, not about who is actually winning right now. The real money and scalable value are locked up with the very few companies that have passed through the FDA gauntlet and then convinced entities like CMS to pay them. Those are the gates that separate a cool idea from a real business. As this space grows up, the difference between a company with a neat algorithm and one that can actually get it adopted in clinics and generate revenue will become painfully obvious. So if you’re looking at this space, forget the flashy market size projections and focus on the hard stuff: their regulatory plan, their reimbursement path, and their demonstrated revenue. That’s where the truth is. CMS National Coverage Determinations